🚨 Hims launches GLP-1 pill, Novo Nordisk threatens to sue!!! (emergency pod with Cremieux)

EMERGENCY EPISODE!!! Hims has launched a compounded oral semaglutide (GLP-1) pill, immediately triggering legal threats from Novo Nordisk. Jonathan Stern is joined by Cremieux, a bioinformatician and leading GLP-1 researcher, to break down what Hims actually released and why the drug-delivery mechanism matters. The conversation examines liposomal delivery vs. Novo’s proprietary SNAC technology, whether Hims’ product will work at all, and whether Novo will sue / how things might shake out if they do. The episode closes with a look at unit economics, next-gen GLP-1s, and what this gambit means for Hims, Novo, and the broader obesity drug market.

00:00 Sponsor: Mochi Health

02:24 Initial reaction to the news

03:56 Science deep dive: liposomal delivery vs. SNAC

06:02 Legal implications and possible lawsuit

18:38 Future of the GLP-1 market (retatrutide, Viking, orforglipron)

25:03 Final risk assessment and conclusions

Not financial, legal, or medical advice